Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA (Leflunomide) in Saudi Arabia

Next Previous
Trial Profile

Post Authorization Safety Study on Assessment of Effectiveness of Additional Risk Minimization Measures Related to ARAVA (Leflunomide) in Saudi Arabia

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leflunomide (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms ARAVA PASS
  • Sponsors Sanofi

Most Recent Events

  • 24 Jun 2025 Status changed from not yet recruiting to recruiting.
  • 24 Jun 2025 Planned End Date changed from 28 Nov 2025 to 3 Dec 2025.
  • 30 Apr 2025 Planned initiation date changed from 15 Apr 2025 to 30 May 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top